---
url: https://www.servicesaustralia.gov.au/multiple-myeloma
title: Multiple myeloma - Health professionals - Services AustraliaServices AustraliaServices Australia
scrapedAt: 2026-02-20T21:41:17.568Z
source: servicesaustralia.gov.au
---
# Multiple myeloma

The PBS subsidises daratumumab, elotuzumab, lenalidomide, pomalidomide and selinexor for patients with multiple myeloma.

## on this page

-   [Patient eligibility](#a1)
-   [Section 100 - Highly Specialised Drugs](#a2)
-   [Section 100 - Efficient Funding of Chemotherapy](#a3)
-   [Authority applications](#a4)
-   [More information](#a5)

Please note: You’ll get an immediate assessment when you request [PBS authorities online](/apply-for-pbs-authority?context=20#accordion1).

## Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with daratumumab, elotuzumab, lenalidomide, pomalidomide and selinexor under the _National Health Act 1953_, section 100 for patients with multiple myeloma.

Patients must be eligible for the [PBS](/pharmaceutical-benefits-scheme) and meet the relevant restriction criteria.

The [Schedule of Pharmaceutical Benefits](http://www.pbs.gov.au/pbs/home) on the PBS website outlines the restrictions for prescribing daratumumab, elotuzumab, lenalidomide, pomalidomide and selinexor.

## Section 100 - Highly Specialised Drugs

### Elotuzumab, lenalidomide, pomalidomide and selinexor

These items are only PBS-subsidised for non-admitted patients, day admitted patients, or patients on discharge who are attending either:

-   an approved private hospital
-   a public hospital.

These items aren’t PBS-subsidised for public hospital in-patients. You must include the hospital name and provider number on the authority application form.

## Section 100 - Efficient Funding of Chemotherapy

### Daratumumab

This item is only PBS-subsidised for non-admitted patients, day admitted patients, or patients on discharge who are attending either:

-   an approved private hospital
-   a public participating hospital.

This item isn’t PBS-subsidised for public hospital in-patients.

## Authority applications

### Lenalidomide

#### Applying for initial treatment as monotherapy for newly diagnosed disease

Applications for initial authority approval to prescribe PBS-subsidised lenalidomide as monotherapy to treat newly diagnosed multiple myeloma can be made in:

-   real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   writing and using [HPOS Form upload](/upload-forms-hpos?context=20)
-   writing and mailed to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [multiple myeloma newly diagnosed monotherapy - lenalidomide - initial authority application form](/pb291?context=20)
-   relevant attachments.

#### Applying for initial treatment as dual therapy for newly diagnosed disease

Applications for initial authority approval to prescribe PBS-subsidised lenalidomide as dual therapy to treat newly diagnosed multiple myeloma can be made in:

-   real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   writing and using [HPOS Form upload](/upload-forms-hpos?context=20)
-   writing and mailed to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [multiple myeloma newly diagnosed dual therapy - lenalidomide - initial authority application form](/pb200?context=20)[](/pb200)
-   relevant attachments.

#### Applying for initial treatment as triple therapy for newly diagnosed disease

Applications for initial authority approval to prescribe PBS-subsidised lenalidomide as triple therapy to treat newly diagnosed multiple myeloma can be made in:

-   real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   writing and using [HPOS Form upload](/upload-forms-hpos?context=20)
-   writing and mailed to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [multiple myeloma newly diagnosed triple therapy - lenalidomide - initial authority application form](/pb293?context=20)[](/pb293)
-   relevant attachments.

#### Applying for initial treatment for progressive disease

Applications for initial authority approval to prescribe PBS-subsidised lenalidomide to treat progressive multiple myeloma can be made in:

-   real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   writing and using [HPOS Form upload](/upload-forms-hpos?context=20)
-   writing and mailed to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [multiple myeloma progressive disease - lenalidomide - initial authority application form](/pb158?context=20)
-   relevant attachments.

#### Applying for continuing treatment for progressive disease

Applications for continuing authority approval to prescribe PBS-subsidised lenalidomide to treat multiple myeloma can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

#### Applying for treatment as triple therapy for relapsed and/or refractory disease

Applications for authority approval to prescribe PBS-subsidised lenalidomide as triple therapy to treat relapsed and/or refractory multiple myeloma can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

### Pomalidomide

#### Applying for initial treatment as dual therapy

Applications for initial authority approval to prescribe PBS-subsided pomalidomide as dual therapy to treat multiple myeloma can be made in:

-   real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   writing and using [HPOS Form upload](/upload-forms-hpos?context=20)
-   writing and mailed to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [multiple myeloma dual therapy - pomalidomide - initial authority application form](/pb214?context=20)
-   relevant attachments.

#### Applying for initial treatment as triple therapy

Applications for initial authority approval to prescribe PBS-subsidised pomalidomide as triple therapy to treat multiple myeloma can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

#### Applying for continuing treatment as dual therapy

Applications for continuing authority approval to prescribe PBS-subsidised pomalidomide as dual therapy to treat multiple myeloma can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

#### Applying for continuing treatment as triple therapy

Applications for continuing authority approval to prescribe PBS-subsidised pomalidomide as triple therapy to treat multiple myeloma can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

### Elotuzumab

As of 1 December 2024, initial treatment with elotuzumab as triple therapy is no longer PBS-subsidised due to commercial reasons. Continuing treatment with elotuzumab as triple therapy remains on the PBS to ensure continuity of the treatment for existing patients.

#### Applying for continuing treatment as triple therapy

Applications for continuing authority approval to prescribe PBS-subsidised elotuzumab as triple therapy to treat relapsed and/or refractory multiple myeloma can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

### Selinexor

#### Applying for initial treatment as dual therapy

Applications for initial authority approval to prescribe PBS-subsidised selinexor as dual therapy to treat relapsed and/or refractory multiple myeloma can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS authority approvals line](/health-professionals-contact-information?context=20#pbsauthority).

#### Applying for continuing treatment as dual therapy

Applications for continuing authority approval to prescribe PBS-subsidised selinexor as dual therapy to treat relapsed and/or refractory multiple myeloma can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS authority approvals line](/health-professionals-contact-information?context=20#pbsauthority).

#### Applying for initial treatment as triple therapy

Applications for initial authority approval to prescribe PBS-subsidised selinexor as triple therapy to treat relapsed and/or refractory multiple myeloma can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS authority approvals line](/health-professionals-contact-information?context=20#pbsauthority).

#### Applying for continuing treatment as triple therapy

Applications for continuing authority approval to prescribe PBS-subsidised selinexor as triple therapy to treat relapsed and/or refractory multiple myeloma can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS authority approvals line](/health-professionals-contact-information?context=20#pbsauthority).

### Daratumumab

#### Applying for initial treatment as triple therapy for untreated disease

Applications for initial authority approval to prescribe PBS-subsidised daratumumab as triple therapy for untreated multiple myeloma can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

#### Applying for initial grandfather treatment as triple therapy for untreated disease

For patients who received non-PBS-subsidised daratumumab treatment before 1 November 2025 for untreated multiple myeloma, apply for initial grandfather authority approval either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

#### Applying for continuing treatment as triple therapy for untreated disease

Applications for continuing authority approval to prescribe PBS-subsidised daratumumab as triple therapy for untreated multiple myeloma can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

## More information

Call the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs) for more information.

Call the [PBS Authority Approvals enquiry line](/health-professionals-contact-information?context=20#pbsauthority) for more information on selinexor.
